A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas.

Trial Profile

A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2013

At a glance

  • Drugs Lonafarnib (Primary) ; Temozolomide (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2011 Actual end date changed from Jan 2010 to June 2011 as reported by ClinicalTrials.gov.
    • 08 Jan 2010 Actual end date (Jan 2010) and actual number of patients (37) added as reported by ClinicalTrials.gov record.
    • 08 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top